News

Dr. Sarah Stevens, Quotient Sciences' VP of Drug Development Sciences, discusses our recent acquisition of Arcinova and the integration of drug substance, drug product, and clinical testing capabilities – all under one or­ganization, in Drug Development & Delivery's Special Feature Report

Quotient Sciences' Dr Shriram Pathak,Senior Research Fellow, has contributed to a publication in the International Journal of Pharmaceutics. The title of the publication is 'Practical and operational considerations related to paediatric oral drug formulation: An industry survey'

Accelerated formulation strategies can aid with cost and time-efficiencies in drug development. However, there are key challenges of which developers must be aware to ensure success. To discuss the primary hurdles to accelerated formulation strategies and best practices for developers.

SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications Potential to address the significant unmet need for new, safe, effective, and non-opioid pain medications Development program funded by the National Institutes of Health (NIH) through a Small Business Technology Transfer (STTR) Fast Track Grant Topline results expected Q3 2022

Quotient's Vice President of Corporate Strategy has been featured in the 2022 Pharma Predictions article on Pharma Manufacturing.

Quotient's Head of Production, Drug Substance, Paul Quigley was featured in a interview with Pharmaceutical Technology regarding the acceleration of development timelines between drug substance and drug product.